Overview

Cangrelor Prasugrel Transition Study

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.
Phase:
Phase 2
Details
Lead Sponsor:
The Medicines Company
Treatments:
Cangrelor
Prasugrel Hydrochloride